Efficacy and safety of a fixed-dose combination of indacaterol and glycopyrronium for the treatment of COPD: A systematic review

Chest

Volumn 146, Issue 2, 2014, Pages 309-317

  Rodrigo, Gustavo J ^a   Plaza, Vicente ^b  

^a HOSPITAL CENTRAL DE LAS FUERZAS ARMADAS   (Uruguay)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPYRRONIUM BROMIDE; GLYCOPYRRONIUM BROMIDE PLUS INDACATEROL; INDACATEROL; PLACEBO; TIOTROPIUM BROMIDE;

CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DRY POWDER INHALER; FORCED EXPIRATORY VOLUME; HUMAN; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ST. GEORGE RESPIRATORY QUESTIONNAIRE; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; GLYCOPYRROLATE; HUMANS; INDANS; MUSCARINIC ANTAGONISTS; PRACTICE GUIDELINES AS TOPIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84904535558     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.13-2807     Document Type: Article

References (34)

1. Gardiner C, Gott M, Payne S, et al. Exploring the care needs of patients with advanced COPD: an overview of the literature. Respir Med. 2010;104(2):159-165.
2. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, updated 2014. Global Initiative for Chronic Obstructive Lung Disease website. http://www.goldcopd.org/uploads/users/files/ GOLD-Report-2014-Jun11.pdf. Accessed June 15, 2014.
3. Vestbo J, Anderson JA, Calverley PMA, et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax. 2009;64(11):939-943.
4. Rodrigo GJ, Plaza V, Castro-Rodríguez JA. Comparison of three combined pharmacological approaches with tiotropium monotherapy in stable moderate to severe COPD: a systematic review. Pulm Pharmacol Ther. 2012;25(1):40-47.
5. Mahler DA, D'Urzo A, Bateman ED, et al; INTRUST-1 and INTRUST-2 study investigators. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison. Thorax. 2012;67(9):781-788.
6. Dahl R, Chung KF, Buhl R, Magnussen H, Nonikov V, Jack D, et al. Efficacy of a new once-daily long-acting inhaled b2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax. 2010;65(6):473-479.
7. Kornmann O, Dahl R, Centanni S, et al; INLIGHT-2 (Indacaterol Efficacy Evaluation Using 150-μg Doses with COPD Patients) study investigators. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J. 2011;37(2):273-279.
8. D'Urzo A, Ferguson GT, van Noord JA, et al. Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir Res. 2011;12:156.
9. Kerwin E, Hébert J, Gallagher N, et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur Respir J. 2012;40(5):1106-1114.
10. Beeh KM, Singh D, Di Scala L, Drollmann A. Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial. Int J Chron Obstruct Pulmon Dis. 2012;7:503-513.
11. Bateman ED, Ferguson GT, Barnes N, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J. 2013;42(6):1484-1494.
12. Vogelmeier CF, Bateman ED, Pallante J, et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med. 2013;1(1):51-60.
13. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151(4):W65-94.
14. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease, updated 2010. Global Initiative for Chronic Obstructive Lung Disease website. http://www.goldcopd.org/uploads/users/files/ GOLDReport-April112011.pdf. Accessed October 18, 2013.
15. ICH harmonised tripartite guideline. Clinical safety data management: definitions and standards for expedited reporting. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use website. http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/ Guidelines/Efficacy/E2A/Step4/E2A-Guideline.pdf. Accessed October 10, 2013.
16. Higgins JPT, Altman DG, Gøtzsche PC, et al; Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
17. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-560. (Pubitemid 37088507)
18. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to Meta-analysis. Chichester (West Sussex), England: John Wiley & Sons Ltd; 2009.
19. Egger M, Smith GD, Altman DG. Statistical methods for examining heterogeneity, combining results from several studies in meta-analysis. In: Deeks JJ, Altman DG, Bradburn MJ, eds. Systematic Reviews in Health care: Meta-analysis in Context. London, England: BMJ; 2001:285-312.
20. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629-634. (Pubitemid 27387172)
21. Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med. 2013;1(3):199-209.
22. Mahler DA, Decramer M, D'Urzo A, et al. Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: BLAZE study. Eur Respir J. 2014;43(6):1599-1609.
23. Novartis Clinical Trials Database. Protocol number CQBA149A1301. Novartis AG website. http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/ displayFile.do?trialResult=9763. Accessed November 5, 2013.
24. Novartis Clinical Trials Database. Protocol number CQBA149A2305. Novartis AG website. http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/ displayFile.do?trialResult=7504. Accessed November 5, 2013.
25. Ultibro Breezhaler. European Medicines Agency website. http://www.ema.europa.eu/ema/index.jsp?curl=/pages/medicines/human/medicines/ 002679/human-med-001691.jsp. Accessed January 13, 2014.
26. Register of Innovative Drugs. Health Canada website. http://www.hc-sc.gc. ca/dhp-mps/alt-formats/pdf/prodpharma/applic-demande/regist/reg-innov-dreng.pdf. Accessed January 25, 2014.
27. Novartis first-in-class once-daily dual bronchodilator Ultibro Breezhaler (QVA149) achieves near simultaneous approval for COPD patients in Europe and Japan. Novartis AG website. http://www.novartis.com/newsroom/mediareleases/en/ 2013/1730580.shtml. Accessed January 13, 2014.
28. Cazzola M, MacNee W, Martinez FJ, et al; American Thoracic Society; European Respiratory Society Task Force on outcomes of COPD. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J. 2008;31(2):416-469.
29. Donohue JF. Minimal clinically important differences in COPD lung function. COPD. 2005;2(1):111-124. (Pubitemid 40776231)
30. Jones PW, Beeh KM, Chapman KR, Decramer M, Mahler DA, Wedzicha JA. Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med. 2014;189(3):250-255.
31. Nishimura K, Izumi T, Tsukino M, Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest. 2002;121(5):1434-1440. (Pubitemid 34499652)
32. Norman P. New dual-acting bronchodilator treatments for COPD, muscarinic antagonists and β2 agonists in combination or combined into a single molecule. Expert Opin Investig Drugs. 2013;22(12):1569-1580.
33. Tamura G, Ohta K. Adherence to treatment by patients with asthma or COPD: comparison between inhaled drugs and transdermal patch. Respir Med. 2007;101(9):1895-1902. (Pubitemid 47163538)
34. Toy EL, Beaulieu NU, McHale JM, et al. Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med. 2011;105(3):435-441.